Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood

Significance Vaccines are one of the most cost-effective public health tools in history and offer a means to probe the human immune system. Recent advances have applied the tools of systems biology to study immune responses to vaccination in humans. Here we describe the application of this “systems vaccinology” approach to studying immunity to vaccination of 14- to 24-mo-old children with the inactivated influenza vaccine, administered with or without the MF59 adjuvant. These results reveal important new insights about the dynamics of the innate and adaptive responses to vaccination in this population, and identify potential correlates of immunity to vaccination in children. The dynamics and molecular mechanisms underlying vaccine immunity in early childhood remain poorly understood. Here we applied systems approaches to investigate the innate and adaptive responses to trivalent inactivated influenza vaccine (TIV) and MF59-adjuvanted TIV (ATIV) in 90 14- to 24-mo-old healthy children. MF59 enhanced the magnitude and kinetics of serum antibody titers following vaccination, and induced a greater frequency of vaccine specific, multicytokine-producing CD4+ T cells. Compared with transcriptional responses to TIV vaccination previously reported in adults, responses to TIV in infants were markedly attenuated, limited to genes regulating antiviral and antigen presentation pathways, and observed only in a subset of vaccinees. In contrast, transcriptional responses to ATIV boost were more homogenous and robust. Interestingly, a day 1 gene signature characteristic of the innate response (antiviral IFN genes, dendritic cell, and monocyte responses) correlated with hemagglutination at day 28. These findings demonstrate that MF59 enhances the magnitude, kinetics, and consistency of the innate and adaptive response to vaccination with the seasonal influenza vaccine during early childhood, and identify potential molecular correlates of antibody responses.

[1]  Eva K. Lee,et al.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans , 2009, Nature Immunology.

[2]  Giuseppe Del Giudice,et al.  The history of MF59® adjuvant: a phoenix that arose from the ashes , 2013, Expert review of vaccines.

[3]  Jill P. Mesirov,et al.  GSEA-P: a desktop application for Gene Set Enrichment Analysis , 2007, Bioinform..

[4]  Sandra Romero-Steiner,et al.  Molecular signatures of antibody responses derived from a systems biology study of five human vaccines , 2022 .

[5]  F. Mosca,et al.  Influenza A/H1N1 MF59-Adjuvanted Vaccine in Preterm and Term Children Aged 6 to 23 Months , 2011, Pediatrics.

[6]  Patrick C. Wilson,et al.  Rapid cloning of high-affinity human monoclonal antibodies against influenza virus , 2008, Nature.

[7]  L. Brammer,et al.  Influenza-Associated Pediatric Deaths in the United States, 2004–2012 , 2013, Pediatrics.

[8]  V. Pascual,et al.  Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children. , 2014, The Journal of infectious diseases.

[9]  Mario Cortese,et al.  Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. , 2011, Vaccine.

[10]  T. Vesikari,et al.  MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. , 2009, Vaccine.

[11]  Pablo Tamayo,et al.  Gene signatures related to B‐cell proliferation predict influenza vaccine‐induced antibody response , 2014, European journal of immunology.

[12]  Mark M. Davis,et al.  Apoptosis and other immune biomarkers predict influenza vaccine responsiveness , 2014, Molecular Systems Biology.

[13]  Audrey Kauffmann,et al.  Bioinformatics Applications Note Arrayqualitymetrics—a Bioconductor Package for Quality Assessment of Microarray Data , 2022 .

[14]  J. Yewdell,et al.  MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines , 2011, Science Translational Medicine.

[15]  B. Pulendran,et al.  Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. , 2012, Blood.

[16]  Volker Brauer,et al.  Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels , 2009, Proceedings of the National Academy of Sciences.

[17]  Eva K. Lee,et al.  Systems Biology of Seasonal Influenza Vaccination in Humans , 2011, Nature Immunology.

[18]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Kolczak,et al.  Effectiveness of the 2003–2004 Influenza Vaccine Among Children 6 Months to 8 Years of Age, With 1 vs 2 Doses , 2005, Pediatrics.

[20]  Molly S Bray,et al.  Integrative genomic analysis of the human immune response to influenza vaccination , 2013, eLife.

[21]  T. Vesikari,et al.  Oil-in-water emulsion adjuvant with influenza vaccine in young children. , 2011, The New England journal of medicine.

[22]  R. Rappuoli,et al.  Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children , 2011, The Pediatric infectious disease journal.

[23]  A. Marchant,et al.  Dissecting the Immune Response to MF59-adjuvanted and Nonadjuvanted Seasonal Influenza Vaccines in Children Less Than Three Years of Age , 2015, The Pediatric infectious disease journal.

[24]  T. Jefferson,et al.  Vaccines for preventing influenza in healthy children. , 2012, The Cochrane database of systematic reviews.